COBRA SHIELD OCT Study

Inclusion Criteria: * Patient \>= 18 years old. * Eligible for percutaneous coronary intervention (PCI). * Patient provides written informed consent. * Patient is willing to comply with follow-up evaluation. * Acceptable candidate for coronary artery bypass graft (CABG) surgery. * Stable angina pectoris or a positive functional ischemia study. * Male or non-pregnant female patient * Patient indicated for elective stenting of up to 2 stenotic lesions in two separate native coronary arteries. * Reference vessel \>=2.5 mm and\<= 4.0 mm in diameter by visual estimate. * Target lesion \<=20 mm in length by visual estimate. * Protected left main lesion with \>50% stenosis. * Target lesion stenosis \>= 70% and \< 100% by visual estimate OR Target lesion stenosis \<70% who meet physiological criteria for revascularization (i.e. positive Fractional Flow Reserve). Exclusion Criteria: * Currently enrolled in another investigational device or drug trial. * Previously enrolled in another stent trial within the prior 2 years. * ANY planned elective surgery or percutaneous intervention within the subsequent 3 months. * A previous coronary interventional procedure of any kind within 30 days prior to the procedure. * The patient requires staged procedure of either the target or any non-target vessel before OCT procedure at 3 months post-procedure. * The target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement. * Previous drug eluting stent (DES) or bare metal stent (BMS) deployment anywhere in the target vessel. * Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial. * Concurrent medical condition with a life expectancy of less than 12 months. * Documented left ventricular ejection fraction (LVEF) \< 50% at the most recent evaluation. * Patients with diagnosis of myocardial infarction (MI) within 72 hours (i.e. CK-MB must be returned to normal prior to enrollment) or suspected acute MI at time of enrollment. * Previous intervention in the target vessel. * History of cerebrovascular accident or transient ischemic attack in the last 6 months. * Leukopenia (leukocytes \< 3.5 x10\^9 / liter). * Neutropenia (Absolute Neutrophil Count \< 1000/mm3) \<= 3 days prior to enrollment. * Thrombocytopenia (platelets \< 100,000/mm3) pre-procedure. * Active peptic ulcer or active GI bleeding. * History of bleeding diathesis or coagulopathy or inability to accept blood transfusions. * Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity to contrast media, which cannot be adequately pre-medicated. * Serum creatinine level \> 2.0 mg/dl within 7 days prior to index procedure. * Patients not responsive to Plavix/ aspirin and or unable to tolerate Plavix/ aspirin for 6 month post procedure. * Patient on or may require anticoagulation therapy within 3 months of index procedure. * Flow limiting dissections observed on OCT * Significant tissue prolapse within the stent observed on OCT * Unprotected left main coronary artery disease * Target vessel with any lesions with greater than 60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line quantitative coronary arteriography (QCA). * Target lesion (or vessel) exhibiting an intraluminal thrombus (occupying \> 50% of the true lumen diameter) at any time. * Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX). * Target lesion with side branches \> 2.0mm in diameter. * Target vessel is excessively tortuous (two bends \> 90˚ to reach the target lesion). * Target lesion is severely calcified. * Thrombolysis In Myocardial Infarction (TIMI) flow 0 or 1 * Target lesion is in a bypass graft